New drug combo aims to outsmart resistant ovarian cancer

NCT ID NCT06856499

Recruiting now Disease control Sponsor: University of Colorado, Denver Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 03, 2026 · Updated 22 times

Summary

This early-phase study tests a new two-drug combination (Cirtuvivint and Olaparib) in people with ovarian, peritoneal, or fallopian tube cancer that no longer responds to platinum chemotherapy. About 50 participants will take the pills at different schedules to find the safest dose and see how well the body tolerates the treatment. The goal is to control the disease, not cure it.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY PERITONEAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

CU Medicine Clinics
RECRUITING

Aurora, Colorado, 80045, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
Universtiy of Colorado Hospital
RECRUITING

Aurora, Colorado, 80045, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

ENDOMETRIOID OVARIAN CANCER FALLOPIAN TUBE CANCER PRIMARY PERITONEAL CANCER